Asthma Control in Elderly Patients With Montelukast

Inclusion criteria

• Patients aged 60 - 75 years
• Patients diagnosed with asthma (NIH, 2007) over six months ago
• Patients maintaining monotherapy of low dose inhaled budesonide (pulmicort 400µg/day or ciclesonide 160 µg/day or fluticasone 250 µg/day) or combination of low dose inhaled budesonide and LABA (Seretide® 250 µg/day or Symbicort® 320 µg/day ) for over a month before the participation in this trial
• Patients not reaching 'well controlled asthma status' with four-week monotherapy of low dose inhaled budesonide (Pulmicort 400 µg/day)
• Patients who sufficiently listen to the purpose and content of this trial and the properties of investigational products and voluntarily agree with the participation to sign a written consent approved by IRB of Ajou University Medical Center before the participation in this trial

Exclusion criteria

• Patients who show a symptom of an acute disease within 28 days before the beginning of this trial (administration of trial medication)
• Volunteers who are found to be unsuitable through screening tests
• Patients with history of hypersensitivity to montelukast or budesonide
• Patients participating in other clinical trial within three months before the beginning of this trial (administration of trial medication)
• current smokers having more than 10PYs of smoking history
• Patients needing administration of a medication which can affect asthma control such as systemic and immunoregulatory drugs (cyclosporin, omalizumab, etc.) due to a disease except asthma